TYMP and liver cancer: By taking advantage of low levels of TK1 and TYMP in normal liver tissue, the use of anticancer thymidine conjugate combined with TYMP suppression could directly target thymidine salvage pathway in liver cancer cells with various levels of TYMP addressed as tumor heterogeneity to be fully inhibited.